| 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 抗结肠炎药(元) | - | 14,674,159.32 | 28,156,840.30 | 15,951,663.42 |
| 抗哮喘药(元) | - | 18,211,325.83 | 31,741,768.92 | 14,823,450.80 |
| 中间体-B6/C6(元) | - | 23,580,345.19 | 41,305,912.28 | 21,888,017.91 |
| 中间体-其他(元) | - | 18,097.34 | 2,436,548.63 | 2,436,548.63 |
| 抗结肠炎类(元) | 30,289,336.31 | - | - | - |
| 抗哮喘类(元) | 71,226,436.41 | - | - | - |
| 营业成本(元) | ||||
| 抗结肠炎药(元) | - | 9,082,097.20 | 17,610,984.60 | 10,156,533.16 |
| 抗哮喘药(元) | - | 7,050,223.90 | 14,657,225.21 | 6,742,417.93 |
| 中间体-B6/C6(元) | - | 18,503,058.80 | 33,845,475.47 | 17,483,982.38 |
| 中间体-其他(元) | - | 13,279.42 | 1,716,583.20 | 1,843,433.87 |
| 抗结肠炎类(元) | 18,746,876.55 | - | - | - |
| 抗哮喘类(元) | 43,395,000.37 | - | - | - |
| 毛利(元) | ||||
| 抗结肠炎药(元) | - | 5,592,062.12 | 10,545,855.70 | 5,795,130.26 |
| 抗哮喘药(元) | - | 11,161,101.93 | 17,084,543.71 | 8,081,032.87 |
| 中间体-B6/C6(元) | - | 5,077,286.39 | 7,460,436.81 | 4,404,035.53 |
| 中间体-其他(元) | - | 4,817.92 | 719,965.43 | 593,114.76 |
| 抗结肠炎类(元) | 11,542,459.76 | - | - | - |
| 抗哮喘类(元) | 27,831,436.04 | - | - | - |
| 毛利率(%) | ||||
| 抗结肠炎药(%) | - | 38.11 | 37.45 | 36.33 |
| 抗哮喘药(%) | - | 61.29 | 53.82 | 54.52 |
| 中间体-B6/C6(%) | - | 21.53 | 18.06 | 20.12 |
| 中间体-其他(%) | - | 26.62 | 29.55 | 24.34 |
| 抗结肠炎类(%) | 38.11 | - | - | - |
| 抗哮喘类(%) | 39.07 | - | - | - |
| 收入构成(%) | ||||
| 抗结肠炎药(%) | - | 25.98 | 27.17 | 28.95 |
| 抗哮喘药(%) | - | 32.24 | 30.63 | 26.90 |
| 中间体-B6/C6(%) | - | 41.75 | 39.85 | 39.72 |
| 中间体-其他(%) | - | 0.03 | 2.35 | 4.42 |
| 抗结肠炎类(%) | 29.84 | - | - | - |
| 抗哮喘类(%) | 70.16 | - | - | - |
| 毛利构成(%) | ||||
| 抗结肠炎药(%) | - | 25.61 | 29.45 | 30.71 |
| 抗哮喘药(%) | - | 51.12 | 47.71 | 42.82 |
| 中间体-B6/C6(%) | - | 23.25 | 20.83 | 23.33 |
| 中间体-其他(%) | - | 0.02 | 2.01 | 3.14 |
| 抗结肠炎类(%) | 29.32 | - | - | - |
| 抗哮喘类(%) | 70.68 | - | - | - |